Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose-Response in Radioimmunotherapy of Lymphoma

Trial Profile

Dose-Response in Radioimmunotherapy of Lymphoma

Phase of Trial: Phase II

Latest Information Update: 03 Sep 2018

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Iodine-131 tositumomab (Primary) ; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top